Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2303]

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof...

ESMO 2024: Latest in EGFR mutated NSCLC ( Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip )

Retifanlimab plus chemo shows PFS benefit in recurrent or metastatic squamous...

Dr Sheela Rao - The Royal Marsden, London, UK

Retifanlimab plus chemo shows PFS benefit in recurrent or metastatic squamous cell carcinoma of the anal canal ( Dr Sheela Rao - The Royal Marsden, London, UK )

ESMO 2024: Latest updates in mRCC

Dr Javier Puente, Dr Guillermo De Velasco, Dr Cristina Suárez and Prof Stéphane...

ESMO 2024: Latest updates in mRCC ( Dr Javier Puente, Dr Guillermo De Velasco, Dr Cristina Suárez and Prof Stéphane Oudard )

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof...

Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )

TACE combined with lenvatinib-pembrolizumab shows improved PFS in intermediate...

Prof Josep Llovet - Hospital Clinic Barcelona, Barcelona, Spain

TACE combined with lenvatinib-pembrolizumab shows improved PFS in intermediate stage liver cancer ( Prof Josep Llovet - Hospital Clinic Barcelona, Barcelona, Spain )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2...

Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies ( Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA )

Trastuzumab deruxtecan effective against brain metastases in HER2-positive...

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )

NKT2152 demonstrates anti-tumor activity in heavily pretreated advanced clear...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

NKT2152 demonstrates anti-tumor activity in heavily pretreated advanced clear cell RCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Status of anti BCMA therapy in myeloma

Dr Dibakar Podder - Tata Medical Center, Kolkata, India

Status of anti BCMA therapy in myeloma ( Dr Dibakar Podder - Tata Medical Center, Kolkata, India )

The promise of CAR T cell therapy for multiple myeloma

Dr Dibakar Podder - Tata Medical Center, Kolkata, India

The promise of CAR T cell therapy for multiple myeloma ( Dr Dibakar Podder - Tata Medical Center, Kolkata, India )

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

More from ecancer